We have demonstrated that the small molecule STAT3 inhibitor galiellalactone [15] inhibits the prostate cancer cell induced generation of monocytes with a myeloid-derived suppressor cell (MDSC)-like phenotype and immunosuppressive factors in both human prostate cancer cells and immune cells ex vivo [16]. This evidence concerns the gene STAT3 and prostate carcinoma.